This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Importance Of Evidence-Based Medicine Presented In New Issue Brief Available From Elsevier

PHILADELPHIA, April 25, 2013 /PRNewswire/ --

Report identifies potential impact of evidence-based medicine in meeting today's healthcare challenges

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the availability of the first in a series of issue briefs on evidence-based medicine (EBM). The issue brief - "Building a Business Case for Evidence-Based Medicine" - reveals the urgent need for EBM, as identified in a roundtable discussion of healthcare industry thought leaders at the CMIO Leadership Forum: Transforming Healthcare Through Evidence-based Medicine , last fall in Chicago.

The roundtable discussion, which featured five physicians representing hospital and healthcare technology CMIOs, research directors and clinical professors, was convened by the developers of ClinicalKey, Elsevier's clinical insight engine designed to help physicians quickly locate accurate answers to their clinical questions. The issue brief, based on the roundtable, emphasizes the need for a business case for EBM as a central necessity to enhancing the American healthcare system. According to findings highlighted within the brief, making the business case for EBM will not be attributed to a single event or destination, but will become more of a process or journey.

"By relying on fast, comprehensive, point-of-care clinical reference tools, clinicians will be better able to pursue the 'shared practice' approach so vital to the patient-centered medical home and accountable care," said David Goldmann, M.D., Vice President and Chief Medical Quality Assurance Officer at Elsevier. "EBM solutions have the potential to accelerate and improve clinical decision making and patient outcomes."

EBM is a long-term, problem-based learning process that involves:

  • Conversion of information needs into focused questions
  • Identification of the best evidence for answering a question
  • Review of evidence for validity and clinical usefulness
  • Application of results to clinical practice
  • Evaluation of how the evidence performs in clinical applications

Identified within this brief are opportunities and strategies that will assist the healthcare system through the EMB journey such as:

  • The U.S. faces a serious shortage of primary care clinicians with an estimated increase in the advanced practice clinician workforce by 15 percent within the year; solutions - many involving technologies like clinician insight engines - are already in sight for many practices.
  • EBM can go a long way in reducing healthcare's failure to implement preventive and patient safety best practices, which typically result in injuries, negative patient outcomes and runaway costs. It can also minimize the burden of overtreatment, where physicians' habits and preferences sometimes trump medical evidence.
  • In an environment where operating costs continue to collide with declining reimbursement, HCOs struggle to maintain revenue, manage overhead and ensure quality, safety and efficiency. EBM will play a critical role in helping healthcare leaders make informed, disciplined choices on a broad array of challenges-from physician integration, hospital consolidation, strategic alignments and new reimbursement models, to technology optimization, risk mitigation, changing populations, and patient engagement.

Although EBM continues to evolve, it has already proven its capacity to influence top-line healthcare issues. An analysis of EBM's potential impact on healthcare's most pressing challenges, including clinician shortages, waste, accountable care and patient engagement is also identified as an imperative need within the healthcare system and further elaborated on in the issue brief.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,251.94 +119.24 0.66%
S&P 500 2,111.34 +6.84 0.32%
NASDAQ 4,989.8040 +26.2770 0.53%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs